SANDOSTATIN 0.05mg/ml price in UAE

Overview

Welcome to Dwaey, specifically on SANDOSTATIN 0.05mg/ml Injection page.
This medicine contains an important and useful components, as it consists of Octreotide (as acetate).
SANDOSTATIN 0.05mg/ml is available in the market in concentration 0.05mg/ml and in the form of Injection.

NOVARTIS PHARMA AG is the producer of SANDOSTATIN 0.05mg/ml and it is imported from SWITZERLAND, The most popular alternatives of SANDOSTATIN 0.05mg/ml are listed downward .

Mode Of Action

Octreotide is a synthetic analogue of somatostatin which acts by suppressing basal and stimulated secretion of growth hormone (GH). It also suppresses LH response to gonadotrophin-releasing hormone and reduces the secretion of gastrin, vasoactive intestinal peptide (VIP), insulin, glucagon, secretin, motilin and pancreatic polypeptide.

Indication

Acromegaly
Variceal haemorrhage
Secretory neoplasms
Following pancreatic surgery
HIV-associated diarrhoea

Precaution

Renal disease; risk of gall bladder disease; DM; hypothyroidism. Pregnancy, lactation, children, elderly. Monitor levels of vitamin B12 during long term therapy. Lactation: Whether octreotide crosses into breast milk is not known; avoid giving to lactating women

Side Effects

>10% Gallbladder problems (>60%): Decreased gallbladder contractility
gallstones
cholecystitis
cholestatic hepatitis
Dysglycemia (25%)
Hypothyroidism (25%)
Bradycardia (25%) 1-10% ECG changes (10%)
Arrhythmia (9%)
Pancreatitis
Upper respiratory tract infection
Fatigue
Headache
Malaise
Rash
Diarrhea
Nausea
Vomiting
Pain at injection site
Joint pain
Blurred vision

Contra indication

Hypersensitivity.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, ?-blockers, diuretics. May increase concentration of bromocriptine. Potentially Fatal: Requirements of insulin may be reduced requiring careful blood-glucose monitoring. Reduction in ciclosporin bioavailability and efficacy.